Roles of Candida albicans Mig1 and Mig2 in glucose repression, pathogenicity traits, and SNF1 essentiality.


Journal

PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074

Informations de publication

Date de publication:
01 2020
Historique:
received: 15 08 2019
accepted: 20 12 2019
revised: 31 01 2020
pubmed: 22 1 2020
medline: 14 4 2020
entrez: 22 1 2020
Statut: epublish

Résumé

Metabolic adaptation is linked to the ability of the opportunistic pathogen Candida albicans to colonize and cause infection in diverse host tissues. One way that C. albicans controls its metabolism is through the glucose repression pathway, where expression of alternative carbon source utilization genes is repressed in the presence of its preferred carbon source, glucose. Here we carry out genetic and gene expression studies that identify transcription factors Mig1 and Mig2 as mediators of glucose repression in C. albicans. The well-studied Mig1/2 orthologs ScMig1/2 mediate glucose repression in the yeast Saccharomyces cerevisiae; our data argue that C. albicans Mig1/2 function similarly as repressors of alternative carbon source utilization genes. However, Mig1/2 functions have several distinctive features in C. albicans. First, Mig1 and Mig2 have more co-equal roles in gene regulation than their S. cerevisiae orthologs. Second, Mig1 is regulated at the level of protein accumulation, more akin to ScMig2 than ScMig1. Third, Mig1 and Mig2 are together required for a unique aspect of C. albicans biology, the expression of several pathogenicity traits. Such Mig1/2-dependent traits include the abilities to form hyphae and biofilm, tolerance of cell wall inhibitors, and ability to damage macrophage-like cells and human endothelial cells. Finally, Mig1 is required for a puzzling feature of C. albicans biology that is not shared with S. cerevisiae: the essentiality of the Snf1 protein kinase, a central eukaryotic carbon metabolism regulator. Our results integrate Mig1 and Mig2 into the C. albicans glucose repression pathway and illuminate connections among carbon control, pathogenicity, and Snf1 essentiality.

Identifiants

pubmed: 31961865
doi: 10.1371/journal.pgen.1008582
pii: PGENETICS-D-19-01346
pmc: PMC6994163
doi:

Substances chimiques

Fungal Proteins 0
Transcription Factors 0
SNF1-related protein kinases EC 2.7.1.-
Protein Serine-Threonine Kinases EC 2.7.11.1
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008582

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI124566
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE026600
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI144878
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Infect Immun. 1997 Dec;65(12):4909-17
pubmed: 9393775
Nucleic Acids Res. 2017 Jan 4;45(D1):D597-D603
pubmed: 27625390
Eukaryot Cell. 2006 Oct;5(10):1726-37
pubmed: 17030998
Mol Microbiol. 2017 Jun;104(6):989-1007
pubmed: 28337802
Yeast. 2007 Oct;24(10):847-60
pubmed: 17605131
Yeast. 1987 Jun;3(2):77-84
pubmed: 3332968
BMC Genomics. 2008 Dec 16;9:601
pubmed: 19087243
Eukaryot Cell. 2009 Oct;8(10):1604-14
pubmed: 19700635
Eukaryot Cell. 2009 Sep;8(9):1314-20
pubmed: 19617394
Nat Genet. 2010 Jul;42(7):590-8
pubmed: 20543849
PLoS Pathog. 2016 Apr 13;12(4):e1005566
pubmed: 27073846
Curr Opin Microbiol. 2018 Jun;43:100-107
pubmed: 29414442
PLoS Pathog. 2019 May 22;15(5):e1007787
pubmed: 31116789
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337445
Front Biosci. 2008 Jan 01;13:2408-20
pubmed: 17981722
Eukaryot Cell. 2004 Feb;3(1):221-31
pubmed: 14871952
mSphere. 2018 Apr 25;3(2):
pubmed: 29695626
Mol Microbiol. 2018 Feb;107(3):277-297
pubmed: 29197127
Eukaryot Cell. 2004 Oct;3(5):1076-87
pubmed: 15470236
mBio. 2018 Sep 11;9(5):
pubmed: 30206168
Genome Biol. 2014;15(12):550
pubmed: 25516281
Mol Cell Biol. 1996 Sep;16(9):4790-7
pubmed: 8756637
Science. 1986 Sep 12;233(4769):1175-80
pubmed: 3526554
Sci Adv. 2015;1(3):e1500248
pubmed: 25977940
Cold Spring Harb Perspect Med. 2014 Oct 01;4(10):
pubmed: 25274758
Cell Microbiol. 2012 Sep;14(9):1319-35
pubmed: 22587014
PLoS Pathog. 2009 Oct;5(10):e1000612
pubmed: 19816560
Cell. 2012 Jan 20;148(1-2):126-38
pubmed: 22265407
PLoS Genet. 2019 Mar 28;15(3):e1008052
pubmed: 30921326
Cell Microbiol. 2006 Jun;8(6):961-71
pubmed: 16681837
Mol Biol Cell. 2009 Nov;20(22):4845-55
pubmed: 19759180
Mitochondrion. 2012 May;12(3):370-80
pubmed: 22353369
Mol Microbiol. 2001 Nov;42(4):981-93
pubmed: 11737641
PLoS Pathog. 2014 Mar 13;10(3):e1003995
pubmed: 24626429
Infect Immun. 2004 Jan;72(1):598-601
pubmed: 14688143
mSphere. 2016 Jun 15;1(3):
pubmed: 27340698
mBio. 2015 Jul 28;6(4):e00986
pubmed: 26220968
FEMS Microbiol Rev. 2003 Apr;27(1):35-64
pubmed: 12697341
J Bacteriol. 2000 Jan;182(2):320-6
pubmed: 10629176
Yeast. 2003 Dec;20(16):1339-47
pubmed: 14663826
Front Microbiol. 2019 Jan 30;10:99
pubmed: 30761119
Bioinformatics. 2009 May 1;25(9):1105-11
pubmed: 19289445
Nat Rev Genet. 2002 Nov;3(11):838-49
pubmed: 12415314
mSphere. 2019 Jun 19;4(3):
pubmed: 31217306
Biochem J. 2011 May 1;435(3):641-9
pubmed: 21323640
Genetics. 1998 Dec;150(4):1377-91
pubmed: 9832517
Microbiology. 2008 Oct;154(Pt 10):3061-3072
pubmed: 18832312
G3 (Bethesda). 2017 Nov 6;7(11):3597-3604
pubmed: 28877970
Yeast. 2000 Mar 15;16(4):325-7
pubmed: 10669870
PLoS Genet. 2016 Dec 9;12(12):e1006487
pubmed: 27935965
Mol Biol Cell. 1997 Aug;8(8):1603-18
pubmed: 9285828
PLoS Pathog. 2010 Feb 05;6(2):e1000752
pubmed: 20140194
J Biol Chem. 2007 Jun 8;282(23):16838-45
pubmed: 17438333
PLoS Biol. 2015 Feb 18;13(2):e1002076
pubmed: 25693184
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Genome Res. 2010 Oct;20(10):1451-8
pubmed: 20810668
J Bacteriol. 2000 Oct;182(20):5730-6
pubmed: 11004171
Mol Cell Biol. 1998 Nov;18(11):6273-80
pubmed: 9774644
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Infect Immun. 1995 Mar;63(3):976-83
pubmed: 7868270
J Mol Evol. 2002 Sep;55(3):336-46
pubmed: 12187386
Cell Metab. 2018 May 01;27(5):988-1006.e7
pubmed: 29719235
Clin Infect Dis. 2001 Dec 15;33(12):1959-67
pubmed: 11702290

Auteurs

Katherine Lagree (K)

Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America.

Carol A Woolford (CA)

Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America.

Manning Y Huang (MY)

Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America.

Gemma May (G)

Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America.

C Joel McManus (CJ)

Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America.

Norma V Solis (NV)

Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America.
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.

Scott G Filler (SG)

Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America.
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.

Aaron P Mitchell (AP)

Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America.
Department of Microbiology, University of Georgia, Athens, Georgia, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH